| Ytd | 25.73% | |
| 1y | 176.49% |
| Open | 6.42 | Prev Close | 6.40 | Low | 6.16 | High | 6.60 | Mkt Cap | 641.62M |
| Vol | 500.71K | Avg Vol | 1.96M | EPS | -1.07 | P/E | N/A | Forward P/E | -3.30 |
| Beta | 1.58 | Short Ratio | 23.98 | Inst. Own | 59.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.09 | 200-d Avg | 4.44 | 1yr Est | 16.44 |
Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmace
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, In
Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This
Achieve Life Sciences Inc. (NASDAQ:ACHV) on Monday received a Complete Response Letter (CRL) from th
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with N
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat
Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmace
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficien
Retail investors talked up five hot stocks this week (June 15 to June 18) on X and Reddit's r/Wa
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Compa
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation N
Achieve Life Sciences (ACHV) is downgraded to 'Hold' due to anticipated CRL of cytisinicline for smo
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior V
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in M
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) has been assigned an average recommenda
Canaccord Genuity analyst Gary Nachman initiates coverage on Achieve Life Sciences (NASDAQ:ACHV)
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Fina
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Fin
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Withi
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing CapabilityCompany Re
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company R
Achieve Life Sciences is rated Buy for risk-tolerant investors after a sharp sell-off tied to FDA ma
Achieve Life Sciences remains a 'Buy' as cytisinicline's NDA for smoking cessation is under FDA revi
Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losse
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.28) per share which missed the
Achieve also announces late-breaking survey data from ORCA-OL, demonstrating participant experience
Biotech stocks have trailed the broader market this year, but more names are starting to show streng
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for can
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart